【作者】 葛小琴；

【导师】 袁瑛；

【作者基本信息】 浙江大学 ， 肿瘤学， 2009， 硕士

【摘要】 背景:吉非替尼和厄洛替尼是选择性表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKI),已被证实对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者有较好的疗效。众多临床研究结果显示:EGFR-TKI对亚洲、女性、非吸烟、腺癌患者有较好的疗效。目的:评价EGFR-TKI对局部晚期或转移性NSCLC患者临床疗效与安全性。方法:经病理确诊的初治或经治的29例晚期NSCLC的患者,吉非替尼250mg/d或厄洛替尼150mg/d口服,至肿瘤进展或发生不可耐受的毒副作用。其中一线治疗14例,二线以上治疗15例。结果:本组29例患者的总有效率(RR)为48.3%,疾病控制率(DCR)72.4%,中位疾病进展时间(PFS)为7.7个月。随访结束时11例患者死亡,死亡患者的中位OS为8个月。主要的的毒副作用是皮疹和腹泻,可耐受。结论:EGFR-TKI治疗晚期非小细胞肺癌,具有较好的疗效和耐受性。更多还原

【Abstract】 BACKGROUND:Gefitinib and erlotinib are small molecule tyrosine kinase inhibitors of the epidermal growth factor receptor(EGFR-TKI).EGFR-TKI is a valid treatment for advanced non-small-cell lung cancer(NSCLC).Increased likelihood of responding to small-molecule therapy is associated with Asian race,female gender, never smoking and adenocarcinoma.PURPOSE:To evaluate the clinical efficacy and tolerability of EGFR-TKI in locally advanced or metastatic NSCLC patients.METHODS:Twenty-nine pathologically verified,locally advanced or metastatic NSCLC patients were treated with gefitinib 250 mg/d or erlotinib 150mg/d, until disease progression or unacceptable toxicity.Fourteen patients were treated as a first-line treatment and 15 patients were treated as a second-line treatment.RESULTS:Overall response rate(RR) of 29 patients was 48.3%,and the disease control rate(DCR) was 72.4%.The median progession-free survival(PFS) was 7.7 month.At the end of follow-up,eleven patients died of lung cancer.The median overall survival of these dead patients was 8 months.The most common drug-related adverse events were skin rashes and diarrhea,but generally mild and tolerant.CONCLUSION:EGFR-TKI is effective and safe in the treatment of patients with locally advanced or metastatic NSCLC.更多还原